-
-
Protechting 6.0 China Roadshow 2024
2024-05-30
-
-
Guo Guangchang: Let’s Invest in Shanghai and Share the Future!
2024-05-26
On 23 May, the “Invest in Shanghai, Sharethe Future” Overseas Promotion Campaign (New York, U.S.) was successfully heldin New York. Shanghai Mayor Gong Zheng delivered a keynote speech at thepromotion event, said, “Shanghai is speeding up the process of building itselfinto an international center of economy, finance, trade, shipping, andtechnologica
-
-
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
2024-05-24
Shanghai, China & JERSEYCITY, N.J. – May 24, 2024 – Shanghai Henlius Biotech, Inc. (2696.HK) andOrganon (NYSE: OGN) today announced that the European Medicines Agency (EMA)has validated the marketing authorization applications (MAAs) for HLX14, aninvestigational Prolia®and Xgeva®(denosumab)biosimilar. Denosumab has been approved in various countries and regi
-
-
Guo Guangchang: Fosun Steadfastly Focuses on Innovation + Globalization
2024-05-23
The 4th BEYOND International Technology Innovation Expo (BEYOND Expo 2024) commenced with a spectacular opening ceremony on 22 May at the Venetian Theatre in the Venetian Macao. At the opening ceremony, Guo Guangchang, Chairman of Fosun International, said that Fosun will steadfastly take innovation and globalization as the core drivers for its development in the next 30 ye
-
-
Guo Guangchang Meets Ho Iat Seng, Chief Executive of Macao SAR, and Attends BEYOND Expo 2024
2024-05-22
On 22 May 2024, Guo Guangchang, Chairman of Fosun International and his delegation met Ho Iat Seng, Chief Executive of Macao Special Administrative Region of the PRC (Macao SAR). Guo Guangchang provided an update on Fosun's business development in Macao SAR. Li Haifeng, Chairman of Fosun Foundation, Wen Xiaodong, Chairman of Fosun Infrastructure G
-
-
The Supplemental Applications of HANDAYUAN(adalimumab injection) for the New Indications Approved by the NMPA
2024-05-22
Shanghai, China, May22,2024 – Shanghai Henlius Biotech, Inc. (2696.HK) announced that the supplementalnew drug applications of its independently developed adalimumab biosimilarHANDAYUAN for the four new indications of polyarticular juvenile idiopathicarthritis, pediatric plaque psoriasis, Crohn’s disease and pediatric Crohn’sdisease have been approved by t
-
-
Fosun Health Receives RMB300 Million Strategic Investment from Foshan Chancheng District State-Owned Capital
2024-05-16
On 14 May, Fosun Health and Foshan Chancheng District Chanxi New City Investment and Construction Co., Ltd. (hereinafter referred to as "Foshan Chanxi City Investment") entered into a "Capital Increase and Share Expansion Agreement". According to the agreement, Foshan Chanxi City Investment proposed to designate entities (including funds,
-
-
With Thousands of Families Painting the “Fosun Lifestyle”, the 6th 515 Fosun Family Day is in Full Swing
2024-05-16
On 15 May, a massive scroll unfurled in the central square of Yuyuan Garden in Shanghai. Close to a hundred families collectively painted the "Fosun lifestyle" scroll, illuminating the "star of Fosun". At the same time, thousands of families painted the "Fosun lifestyle" scroll in 20 commercial districts and communities such as Shanghe Yinxiang in Ru
-
-
Fosun International Earns a Spot on “2024 Fortune China ESG Impact List”
2024-05-16
On 13 May 2024, Fortune China magazine released the 2024 China ESG Impact List, and Fosun International Limited (“Fosun International”or the “Company”) (HKEX stock code: 00656) was included in the list, highlighting its outstanding performance and industry leadership in the areas of environmental, social and governance (ESG).FortuneChinapointed out